Skip to main content

Table 2 Changes in levels of Th17-cells and Th17-related cytokines in RA patients with different therapeutic responses

From: Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

 

Moderate-good responders (n= 36)

Non-responders (n= 12)

Th17 cells (%)

  

   Before Rx.

1.13 ± 0.16

2.94 ± 0.77#

   After Rx.

0.79 ± 0.11***

4.23 ± 0.80*

IL-17 level (pg/ml)

  

   Before Rx

43.1 ± 7.0

92.1 ± 22.2#

   After Rx

27.8 ± 3.8***

148.6 ± 31.5*

IL-6 level (pg/ml)

  

   Before Rx

282.9 ± 37.1

453.7 ± 120.9

   After Rx

171.7 ± 22.2*

471.6 ± 124.0

IL-21 level (pg/ml)

  

   Before Rx

1147.0 ± 216.3

863.5 ± 133.9

   After Rx

769.8 ± 104.7**

942.9 ± 140.4

IL-23 level (pg/ml)

  

   Before Rx

166.1 ± 35.1

158.4 ± 67.6

   After Rx

83.3 ± 19.7***

161.3 ± 63.3

TNF-α level (pg/ml)

  

   Before Rx

22.0 ± 2.4

29.2 ± 7.2

   After Rx

11.0 ± 1.3***

15.2 ± 3.9**

RF titer (IU/ml)

  

   Before Rx

116.6 ± 32.7

368.7 ± 257.9

   After Rx

101.2 ± 28.2

440.0 ± 324.4

Anti-CCP titer (IU/ml)

  

   Before Rx

58.7 ± 9.6

72.4 ± 22.0

   After Rx

51.8 ± 8.7**

68.8 ± 20.3

  1. Data are presented as mean ± SEM; RA, rheumatoid arthritis. *P < 0.05, **P < 0.005, ***P < 0.001, versus before anti-TNF-α treatment in each group
  2. #P < 0.01, versus moderate-good responders.
  3. Anti-CCP, anti-cyclic citrullinated peptide antibodies; IL, interleukin; RF, rheumatoid factor; Rx, treatment; Th17, type 17 helper T cell; TNF-α, tumor necrosis factor-α.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us